Impact of a Wearable Activity Tracker on Disease Flares in Spondyloarthritis: A Randomized Controlled Trial
- Others:
- Université Côte d'Azur, Rheumatology Department, CHU de Nice
- Université Côte d'Azur (UCA)
- Laboratoire Motricité Humaine Expertise Sport Santé (LAMHESS) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université de Toulon (UTLN)-Université Côte d'Azur (UCA)
- Département de Santé publique [CHU Nice] ; Centre Hospitalier Universitaire de Nice (CHU Nice)
- Hôpital Princesse Grace [Monaco]
- Rheumatology Department, CHPG Monaco
- Physical and rehabilitation medicine, Nice University Hospital
- Institut de Biologie Valrose (IBV) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
Description
Objective To evaluate the impact of a wearable activity tracker used to encourage physical activity, on disease flares in patients with spondyloarthritis (SpA). Methods This randomized controlled trial involved randomizing 108 patients with SpA into tracker and nontracker groups. The participants were then subjected to assessments of disease activity, performance (6-minute walk test), and quality of life (QOL; 36-item Short Form Health Survey) at the 12th, 24th, and 36th week. The primary outcome was the change in the frequency of flare episodes (categorized as no flare, flare in ≤ 3 days, and flare in > 3 days) between baseline and 12 weeks. Results The results of the study showed that at the 12th week, the mean change (∆) of the number of flares improved in both groups: −0.32 (95% CI −0.66 to 0.02) and −0.38 (95% CI −0.68 to −0.09) in the tracker and nontracker group, respectively. However, the between-group differences were insignificant ( P = 0.87). Performance scores improved in both groups at the 12th, 24th, and 36th week (all P < 0.01). The different dimensions of QOL also improved at the 12th week ( P < 0.01). Conversely, moderate flares ( P < 0.01) and performance ( P < 0.01) improved over time; however, the influence over time of a wearable activity tracker was not significant ( P = 0.29 and P = 0.66, respectively). Conclusion The use of a wearable activity tracker did not affect the number of flares, performance, or QOL of patients with SpA. Nevertheless, this study confirmed the benefits of physical activity on flares, disease activity, QOL, and physical performance in patients with SpA. (Move Your Spondyl "Better Live Its Rheumatism With the Physical Activity"; ClinicalTrials.gov : NCT03458026 )
Abstract
International audience
Additional details
- URL
- https://hal.science/hal-04149018
- URN
- urn:oai:HAL:hal-04149018v1
- Origin repository
- UNICA